https://www.selleckchem.com/pr....oducts/Lapatinib-Dit
RESULTS IHC studies demonstrated the overexpression of BRD4 in NFPA and GHPA. In vitro and in vivo studies showed that treatment with the BRD4 inhibitor ZBC-260 significantly inhibited the proliferation of PA cells. Further mechanistic studies revealed that ZBC-260 could downregulate the expression of c-Myc, Bcl2 and related genes, which are vital factors in pituitary tumorigenesis. CONCLUSION In this study, we determined the overexpression of BRD4 in NFPA and GHPA and assessed the effects of BRD4 inhibitors on PA cells in
Like
Comment
Share
